Patients with ROS1 across the world want the same thing: to improve their prognosis, life expectancy and quality of life.
This is why a new research group at the University of Cologne, headed by Prof. Jürgen Wolf and Dr. Matthias Scheffler, focussing in particular on ROS1 translocation, is needed. We want to improve our understanding of how this disease begins, progresses and develops resistance to treatment. We want to facilitate access to known and effective treatments that are not yet authorised and accelerate the testing of new treatments. We want to make cancer with ROS1 gene modifications a controllable chronic disease.
If you want to help this research, please find more information in this PDF:
research group ROS1